MatrixCare, which specializes in cloud-based electronic health record software for out-of-hospital care, contributed roughly $220 million to ResMed’s $5.1 billion annual revenue for 2025. ResMed CEO Mick Farrell stated the divestiture aligns with the company’s 2030 portfolio management goals. To ensure operational stability, the companies will enter a transition services agreement covering existing systems and daily workflows.
In section Market Quotes
ResMed Divests MatrixCare for $490 Million
ResMed is offloading its MatrixCare division to private equity firm Frazier Healthcare Partners in an all-cash deal valued at $490 million. The move marks a strategic shift for the medical equipment manufacturer, which plans to funnel the proceeds back to shareholders through an accelerated stock buyback program.
Frazier General Partner Ryan Lucero noted the acquisition aims to improve outcomes within the post-acute care sector. Simultaneously, ResMed disclosed details regarding its recent Noctrix acquisition, which is projected to add $30 million in revenue while impacting fiscal 2027 adjusted earnings per share by 20 cents.
Comments (0)
No comments yet. Be the first!